Pemetrexed clinical studies in performance status 2 patients with non-small cell lung cancer (Review)

RALPH ZINNER1*, CARLA VISSEHEN GRUL2, DAVID R. SPIGEL3 and COLEMAN OBASAJU4

1Departments of Investigational Cancer Therapeutics, and Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; 2EU Lead, Late Phase Development, Lilly Oncology, Lilly Nederland B.V., 3991 RA Houten, The Netherlands; 3Sarah Cannon Research Institute, Nashville, TN 37203; 4Eli Lilly and Company, Indianapolis, IN 46285, USA

Received July 15, 2015; Accepted September 4, 2015

DOI: 10.3892/ijo.2015.3219

Abstract. Because poor performance status (PS) is an independent prognostic factor in non-small cell lung cancer (NSCLC), PS scores are widely used by oncologists to make treatment decisions. Advanced NSCLC patients with an Eastern Cooperative Oncology Group PS of 2 have poor prognoses and are frequently excluded from clinical trials. This article reviews the efficacy and safety of pemetrexed in this patient group. We identified English-language literature (through March 2015) involving completed and ongoing studies through searches of PubMed, meeting abstracts, ClinicalTrials.gov and the European Clinical Trials Register; search terms included ‘pemetrexed,’ ‘NSCLC’ and ‘PS2’. Only studies reporting ≥1 subset analysis of PS2 patients receiving pemetrexed were chosen. Our search identified a total of ten pemetrexed studies in PS2 patients. Eight studies included only chemonaive patients, one study included both chemonaive patients and patients with one prior chemotherapy regimen and one study included only patients with one prior regimen. In subset analyses in these studies, PS2 patients had worse outcomes than PS0-1 patients regardless of treatment. In a phase 3 study, chemonaive advanced NSCLC patients with PS2 receiving pemetrexed-carboplatin versus pemetrexed experienced improved overall survival [hazard ratio (HR)=0.62; P=0.001], progression-free survival (HR=0.46; P<0.001) and response (P=0.032). This review confirms the poorer outcomes in PS2 vs. PS0-1 patients. Although it is not an approved combination therapy, in clinical studies, PS2 patients treated with pemetrexed plus carboplatin as first-line therapy had improved response rates and survival. Additional research on PS2 patients is needed.

Contents

1. Introduction
2. Methods
3. Results
4. Discussion
5. Conclusion

1. Introduction

Globally, lung cancer is the most commonly diagnosed cancer and leading cause of cancer-related death in males, and the fourth most commonly diagnosed cancer and second most common cause of cancer-related death in females (1). In a meta-analysis published in 1995, cisplatin-based chemotherapy showed a small but statistically significant survival advantage compared with best supportive care (BSC) for treatment of non-small cell lung cancer (NSCLC) (2). The current standard of care for advanced/metastatic NSCLC evolved to platinum-based doublet therapy (or triplet therapy when bevacizumab is included) as first-line therapy of medically fit patients with advanced NSCLC and a performance status (PS) of 0-1 (3-5). More recently, patients with epidermal growth factor receptor mutations are recommended to have first-line erlotinib, gefitinib or afatinib, and patients with anaplastic lymphoma kinase translocations should be treated with crizotinib as first-line therapy (4,5).

Clinicians use PS to make clinical decisions regarding the use of chemotherapy and to make judgments regarding medical fitness for chemotherapy. PS scales are used in an attempt to quantify the well-being and daily life activities of patients with cancer. Additionally, PS is used to determine whether chemotherapy dose adjustments are needed. In clinical trials, PS is used as an enrollment criterion.

The most widely used scales for measuring PS are the Karnofsky Performance Status (KPS) score and the Eastern Cooperative Oncology Group (ECOG) scale (6,7). The KPS
scale, published in 1949, is expressed as percentages along a continuum with 0% denoting death and 100% denoting normal, no complaints, no evidence of disease (7). This scale was developed to enable physicians to evaluate a patient's ability to survive and tolerate chemotherapy. The ECOG scale uses a five-point system, with 0 being asymptomatic and 5 denoting death (6). Conversions between the KPS and ECOG PS scales were validated in lung cancer patients, in which ECOG PS scores of 0-1, 2 and 3-4 are approximately equivalent to KPS scores of 80-100, 60-70 and 10-50%, respectively (8).

PS scales are used by clinicians to guide treatment decisions (9). Patients with an ECOG PS score of 2 are 'ambulatory and capable of all self-care but unable to carry out any work activities; up and about >50% of waking hours' (6). The percentage of lung cancer patients with a PS of 2 is estimated to be 20-40% (8-11). Poor PS is an independent prognostic factor in NSCLC (12-16). Consequently, patients with a PS of 2 are frequently excluded from clinical trials because of historically poorer outcomes and more toxicity compared with patients with a PS of 0-1 (17).

Patients with a PS of 2 are a heterogeneous group (17). PS is affected by both cancer-related symptoms and comorbidities that are unrelated to cancer (9). In a recent review of the literature (18), chemotherapy use and outcomes among patients with cancer (including lung cancer) with comorbidities were generally inferior to patients without comorbidities; however, there was insufficient evidence to conclusively determine the relationship between decreased chemotherapy use and inferior survival. These types of observations and clinical experience may prompt clinicians to treat patients with lung cancer who have a PS of 2 due to lung cancer symptoms more aggressively than patients with lung cancer who have a PS of 2 due to comorbidities.

In first-line treatment of PS2 patients with advanced NSCLC, the decision to use single-agent versus combination therapy is clinically challenging. Until recently, single agents have been the preferred treatment for these patients, but randomized clinical trials have shown that PS2 patients with advanced chemo naive NSCLC can benefit from combination therapy (relative to monotherapy) without excessive toxicity (19-24). Emerging data have prompted the revision of treatment guidelines (Table I) (3,4).

Pemetrexed (Alimta®, LY231514), a third-generation multi-targeted antifolate (25), is currently approved in the United States (US) and European Union for use in locally advanced or metastatic non-squamous NSCLC in initial first-line treatment in combination with cisplatin, as a single agent in maintenance treatment for patients whose disease has not progressed after 4 cycles of platinum-based first-line chemotherapy, and as second-line treatment after prior therapy (26-32); pemetrexed is also approved for use in combination with cisplatin for unresectable malignant pleural mesothelioma (33). The pemetrexed first-line (31) and maintenance (27,29,30) NSCLC registration trials enrolled patients with a PS of 0-1, whereas the second-line registration trial enrolled patients with a PS of 0-2 (28). Herein, we present a review of the literature on studies involving the use of pemetrexed in patients with advanced NSCLC and a PS of 2. We also discuss the efficacy and safety of pemetrexed in this patient population.

2. Methods

English-language literature involving completed studies was identified through searches of PubMed (database inception through March 2015), proceedings of the American Society of Clinical Oncology (ASCO) (database inception through March 2015) and European Society of Medical Oncology (ESMO) meeting abstracts (from 2011 through March 2015). Ongoing clinical trials were identified by using ClinicalTrials.gov (34) and the European Clinical Trials Register (35); only studies that specifically targeted patients with a PS of 2 were included. Search terms included combinations of ‘pemetrexed,’ ‘NSCLC,’ ‘performance status,’ ‘performance status 2,’ ‘PS2’ and ‘poor performance status’. References within identified articles were also reviewed. Only studies that reported at least one subset analysis for PS2 patients receiving pemetrexed or reported on PS2 patients receiving pemetrexed exclusively were chosen for this review.

3. Results

Our search identified a total of ten pemetrexed studies in PS2 patients (Tables II-IV) (19,28,36-43). Eight studies included only chemo naive patients (19,36-38,40-43), one study included both chemo naive patients and patients with one prior chemotherapy regimen (39) and one study included only patients with one prior regimen (28). Only one randomized trial was dedicated to the use of pemetrexed exclusively in chemo naive patients with an ECOG PS of 2 (19). In some studies, data pertaining specifically to PS2 patients were limited. All but two trials (36,43) included folic acid and vitamin B12 supplementation and dexamethasone per the pemetrexed label (26). Six trials included patients with squamous histology (19,28,36,37,40,41), as these trials predated the revision of the pemetrexed indication excluding squamous patients (26).

Completed pemetrexed clinical trials including PS2 patients

First-line pemetrexed single-agent therapy. Clarke et al performed an international, single-arm, phase 2 trial in patients with advanced NSCLC (36). Eligibility requirements included being chemo naive, having stage IIIA/B or IV NSCLC (of both squamous and non-squamous histology) and having an ECOG PS of 0-2 (Table II). Patients received 600 mg/m² pemetrexed every 3 weeks (q3w) for a maximum of 12 cycles (without vitamin supplementation). The aims were to investigate the activity and toxicity of pemetrexed in this patient population.

Fifty-nine patients were enrolled (36). The median age was 59 years (range, 39-74 years), 32% (19/59) of patients had a PS of 2, 34% were female, 66% had stage IV disease, and 17% of patients had squamous histology. The response rate in patients with a PS of 2 was 5%, whereas it was 18% in patients with a PS of 0-1 and 16% overall. The effects of PS on dose delivery and tolerability were not reported. On the basis of response rate, the authors concluded that pemetrexed treatment should be restricted to patients with a PS of 0-1. It should be noted that the pemetrexed dose used in this trial exceeded the now registered dose of 500 mg/m², and this trial predated the use of vitamin supplementation and allowed patients with squamous histology. As such, toxicities in this trial are more pronounced than in later studies.
Gridelli et al performed an open-label, randomized, phase 2 trial comparing single-agent pemetrexed (500 mg/m² q3w for 8 cycles) to sequential pemetrexed-gemcitabine (pemetrexed 500 mg/m² q3w for cycles 1 and 2 followed by 1,200 mg/m² gemcitabine on days 1 and 8 q3w for cycles 3 and 4 repeated once for a total of 8 cycles) (Table II) (37). Eligible patients had stage IIIB or IV NSCLC (of both squamous and non-squamous histology), were chemonaive, had an ECOG PS of 0-2, and were at least 70 years old or less than 70 years old, but ineligible for platinum-based chemotherapy. The primary endpoint was time-to-progressive disease (TtPD).

Of the 92 randomized patients, 87 were treated (44 pemetrexed and 43 pemetrexed-gemcitabine) (37). The median age was 73 years (range, 58-82 years) for patients receiving pemetrexed and 73 years (range, 61-83 years) for those receiving pemetrexed-gemcitabine; 14/44 patients (32%) receiving pemetrexed and 17/43 patients (40%) receiving pemetrexed-gemcitabine had a PS of 2. Among patients receiving pemetrexed and pemetrexed-gemcitabine, ~21 and 33% were female, 82 and 81% had stage IV disease, and 25 and 35% had squamous histology, respectively. Because many patients died in the absence of documented progression, there was a high rate of censoring for TtPD. Consequently, progression-free survival (PFS) was added retrospectively as this endpoint was expected to have less censoring than TtPD. The median PFS was 3.3 months for each treatment arm, and the median overall survival (OS) was 4.7 months for pemetrexed and 5.4 months for pemetrexed-gemcitabine. In an exploratory analysis of patients with a PS of 2 who received pemetrexed and pemetrexed-gemcitabine, the median PFS was 1.3 and 1.9 months, respectively; in patients with a PS of 0-1, the median PFS was 4.4 months for pemetrexed and 3.7 months for pemetrexed-gemcitabine. The median OS was 1.8 and 3.9 months in patients with a PS of 2, and was 5.2 and 7.6 months in patients with a PS of 0-1 for pemetrexed and pemetrexed-gemcitabine, respectively. The between-arm differences were not significant for the subgroups. The effects of PS on dose delivery and tolerability were not reported. The authors noted that the study confirmed that a PS of 2 predicted poor outcomes and that studies dedicated to patients with a PS of 2 were needed. The authors concluded that either treatment was appropriate for further study in more homogeneous patient populations such as elderly patients who are unsuitable for treatment with platinum-based combination chemotherapy (i.e., patients with a PS of 2). Pemetrexed is not approved as a single-agent first-line therapy or in combination with gemcitabine. There was no blinding in the study, thus investigator bias may have been introduced, and there was a high level of censoring for TtPD (37).

**Second-line pemetrexed single-agent therapy.** In a large, phase 3, registration trial, Hanna et al randomized previously-treated patients with advanced NSCLC to receive pemetrexed (500 mg/m² q3w) or docetaxel (75 mg/m² q3w) (Table II) (28). Eligibility criteria included having stage III or IV NSCLC (of both squamous and non-squamous histology), having received 1 prior regimen for advanced disease and having an ECOG PS of 0-2. This was a noninferiority trial with a primary endpoint of OS. At the time of this study, single-agent docetaxel had already been approved as second-line therapy (44,45).
## Table II. Published completed studies of single-agent pemetrexed in PS2 patients.

| Authors, year (ref.), Treatment type, Endpoint | Study design/ phase | Study population | Treatment⁴ | ORR | mPFS and mOS | Grades 3 or 4 AEs occurring in patients in either arm and deathsᵇ |
|-----------------------------------------------|---------------------|-----------------|------------|-----|-------------|------------------------------------------------------------------|
| Clarke et al, 2002 (36) | Single-arm/ phase 2 | N=59 enrolled; n=57 evaluable for ORR; ≥18 years of age; ECOG PS ≤2; stage III/IV NSCLC; All histologies | Pemetrexed 600 mg/m² q3w up to 12 cycles | All: 15.8% (95% CI, 7-28) | PS0-1: 18% (95% CI, NR) | PS2: 5% (95% CI, NR) |
| First line | | | | | All: NR | PS0-1: NR | PS2: NR |
| | | | | | All: 7.2 months | PS0-1: NR | PS2: NR |
| Primary endpoint= response and toxicity | | | | | All: 5.4 months | PS0-1: 7.6 months’ | PS2: 3.9 months’ |
| Gridelli et al, 2007 (37) | Open-label randomized/ phase 2 | N=92 enrolled; ≥70 or <70 years of age if ineligible for platinum-based chemotherapy; ECOG PS of 0-2; stage IIIb or IV NSCLC; All histologies | Pemetrexed 500 mg/m² q3w up to 8 cycles vs. Pemetrexed 500 mg/m² on day 1 for cycles 1 and 2 followed by gemcitabine 1,200 mg/m² on days 1 and 8 q3w for cycles 3 and 4, repeated once for a total of 8 cycles | All Pem: 4.5% (95% CI, 0.6-15.5) | Sequential Pem/Gem: 11.6% (95% CI, 3.9-25.1) | All Pem: 5.0% (95% CI, 3.9-25.1) |
| First line | | | | | All Pem/Gem: 4.7 months (95% CI, 3.2-6.8) | PS0-1: 5.2 months’ | PS2: 1.8 months’ |
| Primary endpoint= TtPD | | | | | PS2: 1.8 months’ | All: 3.3 months | PS0-1: 4.4 months’ |
| | | | | | PS2=1.3 months’ | Pem: mOS | All: 4.7 months | Pem: mOS |
| | | | | | (95% CI, 2.0-4.4) | (95% CI, 3.9-25.1) | (95% CI, 2.0-4.4) |
| | | | | | Febrile neutropenia 4.7/0 | Febrile neutropenia 4.7/0 | Febrile neutropenia 4.7/0 |
| | | | | | Mucositis 7.0/0 | Mucositis 7.0/0 | Mucositis 7.0/0 |
| | | | | | Deaths: not reported | ’Asymptomatic |
| Hanna et al, 2004 (28) | Randomized/ phase 3 | N=571 randomized; ECOG PS of 0-2; stage III or IV NSCLC; 1 prior chemotherapy for advanced disease; | Pemetrexed 500 mg/m² q3w vs. Docetaxel 75 mg/m² q3w | All Pem: 9.1% | All Doc: 8.8% | All Pem: 9.1% |
| Second line | | | | | All Doc: 8.3 months | PS0-1: NR | PS0-1: 9.4 months’ |
| Noninferiority | | | | | PS2: NR | PS2: 3.6 months |
| Primary endpoint=OS | | | | | All Pem: Neutropenia 5.3 | | Neutropenia 5.3 |
| | | | | | Anemia 4.2 | | Anemia 4.2 |
| | | | | | Febrile neutropenia 1.9 | | Febrile neutropenia 1.9 |
| | | | | | Neutropenia w/ infection 0 | | Neutropenia w/ infection 0 |
| | | | | | Fatigue 5.3 | | Fatigue 5.3 |
Of the 571 randomized patients, 265 received pemetrexed and 276 received docetaxel (28). The median age (pemetrexed/docetaxel) was 59 (range, 22-81 years)/57 years (range, 28-87 years), 11/12% had a PS of 2, 31/25% were female, 75/75% had stage IV disease and 28/32% had squamous histology. The median OS in PS2 patients was (pemetrexed/docetaxel) 3.6/2.2 months, whereas it was 9.4/9.1 months in PS0-1 patients and 8.3/7.9 months overall; the between-arm differences were not significant. Factors significantly associated with increased survival were: PS of 0 or 1 (HR=0.25, 95% CI, 0.19-0.34; P<0.001), stage III disease (HR=0.77, 95% CI, 0.60-0.97; P=0.026), and longer time since last chemotherapy (HR=0.74, 95% CI, 0.60-0.97; P=0.004). The effects of PS on dose delivery and tolerability were not reported.

An open-label, phase 2, single-arm study is investigating the use of pemetrexed monotherapy (plus vitamin supplementation) in PS2 patients with advanced NSCLC (Table III) (39). The study included both chemo naive patients and patients with one prior chemotherapy who had stage IIIB or IV NSCLC, and a Zubrod PS2 or PS3. This study has been completed, but study data are not available yet.

First-line pemetrexed combination therapy. Blakely et al performed a single-arm phase 2 trial testing the combination of pemetrexed (500 mg/m² q2w) and gemcitabine (1,500 mg/m² q2w) for up to 12 cycles (Table IV) (40). Eligibility criteria included age ≥65 years, ECOG PS of 0-2, and stage IIIB or IV NSCLC (of both squamous and non-squamous histology); patients <65 years were eligible if they had a PS of 2. Patients had to be chemo naive. The primary endpoint was objective response rate (ORR). Forty-five patients with a mean (SD) age of 72 (6.7) years (range, 46.1-88.0 years) were enrolled, 13/45 patients (29%) had an ECOG PS of 2, 44% were female, and 89% had stage IV disease (40). Only 5/13 patients (38%) with a PS of 2 were evaluable for response. Of these, there were no responses, but 1 patient had stable disease lasting longer than 24 weeks. In contrast, 26/32 patients (81%) with a PS of 0-1 were evaluable for response, and among these the ORR (complete response (CR) + partial response (PR)) was 25% (CI, 13.3%-42.1%). The difference in response between patients with a PS of 2 and those with a PS of 0-1 was not significant (P=0.083); however, this subgroup analysis was unplanned and few patients with a PS of 2 were evaluable. The median PFS was 1.6 months (CI, 1.2-2.0) in patients with a PS of 2, 3.8 months (CI, 2.9-4.8) in patients with a PS of 0-1, and 3.5 months (CI, 2.3-4.6) overall. The median PFS difference between patients with a PS of 2 and those with a PS of 0-1 was statistically significant (P=0.011), although this subgroup analysis was unplanned.

Of the 6 patients who died during the study, all had a PS of 2 at baseline (40). However, none of these deaths were attrib-
Table III. Unpublished clinical trials of pemetrexed in PS2 patients.

| Sponsor/identifier | Status* | Study design/phase | Study population¹ | Treatment | Primary endpoint |
|-------------------|---------|--------------------|-------------------|-----------|-----------------|
| Fudan University (China)/Clinicaltrials.gov: NCT01860508 (38) | Recruiting | Open-label single-arm | Non-squamous stage IV NSCLC; ≥65 years or PS2; First-line; Target=94 | Pemetrexed/ carboplatin → Pemetrexed maintenance (regimen not reported) | PFS |
| MD Anderson Eli Lilly and Company Clinicaltrials.gov: NCT00508144 (39) | Completed | Open-label single-arm/phase 2 | Stage IIIB or IV NSCLC; Zubrod PS2 or PS3; ≤1 prior chemotherapy; second-line Target=70 | Pemetrexed 500 mg/m² q3w, until progression or unacceptable toxicity | ORR (PS2) Descriptive (PS3) |

¹As of 19 March 2015. *Patients received folic acid and vitamin B12 and dexamethasone (38,39). NSCLC, non-small cell lung cancer; ORR, objective response rate; PFS, progression-free survival; PS, performance status; q3w, every 3 weeks.}

utable to treatment-related adverse events (AEs) and the AEs experienced by these patients were similar to those of other patients. The probability of experiencing a grade 3 or 4 AE did not differ between these 6 patients and the entire cohort. Overall, the occurrence of grade 3 or 4 AEs was unrelated to PS (and unrelated to disease stage, ethnicity, elderly status, and histological subtype). The authors concluded that patients with a PS of 2 fared poorly in this trial, regardless of age, and that there was high early mortality with poor responses to therapy.

In an open-label phase 3 trial, Grønberg et al. randomized patients with advanced NSCLC to pemetrexed (500 mg/m² on day 1 q3w) with carboplatin (AUC=5 on day 1 q3w) or gemcitabine (1,000 mg/m² on days 1 and 8 q3w) with carboplatin (AUC=5 on day 1 q3w); regimens were repeated for up to 4 cycles (Table IV) (41). Eligibility criteria included being chemo naive, having stage IIIB or IV NSCLC (of both squamous and non-squamous histology), and having a WHO PS of 0-2. The primary endpoint was health-related quality of life (HRQoL), as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30.

Overall, 446 patients were enrolled in this study (41). The median age was 64 (range, 35-90 years) for patients receiving pemetrexed-carboplatin and 66 years (range, 25-84 years) for patients receiving gemcitabine-carboplatin; 47/219 patients (21.5%) and 49/217 patients (22.6%) had a WHO PS of 2. A total of 44 and 41% of the patients receiving pemetrexed-carboplatin and gemcitabine-carboplatin were female, respectively, and 71 and 72% had stage IV NSCLC, respectively. There were no significant between-arm differences for the primary HRQoL endpoints. Of the enrolled patients, 436 patients (219 receiving pemetrexed-carboplatin; 217 receiving gemcitabine-carboplatin) were eligible for the survival analysis. Among patients who received respective treatments of pemetrexed-carboplatin and gemcitabine-carboplatin, the median OS was 4.3 and 5.1 months for patients with a PS of 2, 8.7 and 7.7 months in patients with a PS of 0-1 and 7.3 and 7.0 months overall. The between-differences were not significant in either PS category. The effects of PS on dose delivery, tolerability, and HRQoL were not reported. The authors noted that OS in the overall/intent-to-treat (ITT) patient population was shorter than other trials investigating gemcitabine with platinum, but this trial had a relatively high proportion of PS2 patients.

To date, the only completed prospective clinical trial evaluating the use of pemetrexed specifically in PS2 patients was performed by Zukin et al. in multiple Brazilian centers and one US center (Table IV) (19). This trial was designed prior to the approval of pemetrexed for first-line therapy (26,31,32) and the knowledge of the interaction between histological subtype and pemetrexed efficacy (46,47). The protocol was later amended to exclude patients with squamous histology. Patients with advanced NSCLC were randomized to receive pemetrexed (500 mg/m² q3w) or pemetrexed (500 mg/m² q3w) with carboplatin (AUC=5 q3w), both for 4 cycles. Eligibility criteria included having an ECOG PS of 2, stage IIIB/IV NSCLC and no prior chemotherapy. The primary endpoint was OS (19). At the main center in Brazil where >60% of the patients were enrolled during this trial, two independent investigators had to agree on the ECOG PS2 assignment before the patient was enrolled (19).

Overall, 217 eligible patients were enrolled, comprising 109 in the pemetrexed arm and 108 in the pemetrexed-carboplatin arm (19). The median age (pemetrexed/pemetrexed-carboplatin) was 65 (range, 40-86 years)/65 years (range, 41-90 years), 41/37% were female, 95/94% had stage IV NSCLC and 11/3% had squamous histology. Comorbidities included (pemetrexed/pemetrexed-carboplatin): hypertension (45.1/44.7%), chronic obstructive pulmonary disease (17.6/11.7%), and diabetes mellitus (7.8/12.6%). Overall, 53.9% of patients receiving pemetrexed completed the planned treatment, in comparison to 70.9% of patients receiving pemetrexed-carboplatin (P=0.012). Reasons for treatment discontinuation included (pemetrexed/pemetrexed-carboplatin): early death (14.7/9.7%), early progression (15.7/7.8%), clinical deterioration (12.7/6.8%) and toxicity (0.1%/9.0%). The authors commented that, during this study, investigator bias may have been introduced regarding patient selection; patients may not be representative of the average ECOG 2 population. In the ITT patient population, patients receiving combination therapy experienced improved OS (HR=0.62, 95% CI, 0.46-0.83;
Table IV. Published studies of pemetrexed-containing combination therapy in PS2 patients.

| Authors, year (ref.), Treatment type, Endpoint<sup>a</sup> | Status | Study design/phase | Study population | Treatment<sup>b</sup> | ORR | mPFS and mOS | Grades 3/4 AEs occurring in patients in any arm and deaths<sup>c</sup> |
|----------------------------------------------------------|--------|-------------------|------------------|----------------------|-----|--------------|---------------------------------------------------------------|
| Blakely <i>et al</i>, 2009 (40)                          | Completed | Prospective, single-arm/ phase 2 trial | N=45 enrolled; ≥65 years of age and/or ECOG PS0-2 or <65 years if PS of 2; Measurable stage IIIB or IV NSCLC; All histologies; 18% SCC 29% PS2 | Pemetrexed 500 mg/m<sup>2</sup> + gemcitabine 1,500 mg/m<sup>2</sup> q2w up to 12 cycles | All: 17.8% (95% CI, 9.3-31.4) **PS0-1**: 25% (95% CI, 13.3-42.1) **PS2**: 0% | mPFS All: 3.5 months (95% CI, 2.3-4.6) **PS0-1**: 3.8 months (95% CI, 2.9-4.8) **PS2**: 1.6 months (95% CI, 1.2-2.0) | All (% Grade 3/Grade 4): Neutropenia 4/18 Anemia 4/0 Febrile neutropenia 4/0 Fatigue/weakness 13/2 Shortness of breath 11/0 Anorexia 7/0 6 deaths, all in patients with PS of 2, none treatment-related |
| Grønberg <i>et al</i>, 2009 (41)                          | Completed | Open-label, randomized/phase 3 | N=446 enrolled; n=436 survival; n=423 safety; stage IIIB or IV NSCLC; WHO PS0-2; All histologies | Pemetrexed 500 mg/m<sup>2</sup> + carboplatin (AUC=5) on day 1 q3w up to 4 cycles | All: 7.3 months (95% CI, 6.1-8.6) **PS0-1**: 8.7 months (95% CI, 7.1-10.3) **PS2**: 4.3 months (95% CI, 3.3-5.4) | mOS All: 7.0 months (95% CI, 5.8-8.2); P=0.63 **PS0-1**: 7.7 months (95% CI, 6.2-9.3); P=0.51 **PS2**: 5.1 months (95% CI, 3.3-7.0); P=0.54 | (% Grade 3/Grade 4) Granulocytopenia 25/15 Thrombocytopenia 13/11 Leukopenia 18/5 Anemia 12/1 % Grade 3 or Grade 4; Neutropenic infection 8 Infection w/o neutropenia 9 |

<sup>a</sup>Endpoint: PS0-1 vs. PS2: P=0.083 **PS0-1 vs. PS2:** P=0.011

<sup>b</sup>Treatment: Pem-Carb: Pemetrexed 500 mg/m<sup>2</sup> + carboplatin (AUC=5) on day 1 q3w up to 4 cycles vs. Gem-Carb: Gemcitabine 1,000 mg/m<sup>2</sup> on days 1 and 8 + carboplatin (AUC=5) on day 1 q3w up to 4 cycles

<sup>c</sup>Death: no difference between treatment groups regarding causes of death
| Authors, year (ref.), Treatment type, Endpoint<sup>a</sup> | Status | Study design/phase | Study population | Treatment<sup>b</sup> | ORR | mPFS and mOS | Grades 3/4 AEs occurring in patients in any arm and deaths<sup>c</sup> |
|---|---|---|---|---|---|---|---|---|
| Zarkin et al, 2013 (19) Completed | Prospective randomized/ phase 3 trial | N=217 enrolled; n=205 treated; Measurable stage IIIB/ IV NSCLC; ECOG PS2; Initially all histologies, protocol later amended to exclude SCC | Pem (n=102): 10.8% SCC 100% PS2 | Pem: Pemetrexed 500 mg/m² q3w up to 4 cycles  Pem-Carb: Pemetrexed 500 mg/m² + carboplatin AUC=5 q3w up to 4 cycles | Pem: 10.5% ; P=0.032  Pem-Carb: 24%*; P=0.001 | 2.8 months (95% CI, 2.5-3.2) | Anemia 11.7; P=0.07  Neutropenia 6.8; P=0.06  Thrombocytopenia 1.0; P=0.57  Dyspnea 5.8; P=0.19  Nausea/emesis 4.9; P=0.21 | Grade 3 or 4 AEs (%) Pem: Anemia 3.9  Neutropenia 1.0  Febrile neutropenia 2.9  Thrombocytopenia 0  Dyspnea 10.8  Nausea/emesis 1.0  Grade 5 AEs 0 |
| First line | | | Pem-Carb (n=103): 2.9% SCC 100% PS2 |  |  | | | |
| Primary endpoint=OS | | | |  | | | | 4 deaths=renal failure, sepsis, pneumonia, and thrombocytopenia (all treatment-related) |
| Authors, year (ref.), Treatment type, Endpoint<sup>a</sup> | Status | Study design/phase | Study population | Treatment<sup>b</sup> | ORR | mPFS and mOS | Grades 3/4 AEs occurring in patients in any arm and deaths<sup>c</sup> |
|---|---|---|---|---|---|---|---|
| Lilenbaum et al, 2013 (42) Ongoing Poster | Ongoing | Prospective, randomized/ phase 2 trial (1:1:1) | N=163 enrolled; n=154 treated; Non-squamous NSCLC; stage IIB or IV; ECOG PS 2 | Arm 1: Pemetrexed 500 mg/m² q3w | 14.6% (95% CI, 6.1-27.8) | Arm 1: mPFS 2.6 months (95% CI, 1.5-5.1) | Arm 1: % Grade 3/ % Grade 4 Arm 1 (N=48): Anemia 8.3/0; Neutropenia 6.3/2.1; Thrombocytopenia 0/2.1; Leukopenia 0/0; Fatigue 18.8/0; Pneumonia 14.6/0; Asthenia 8.3/0; Cellulitis 8.3/0; Dyspnea 6.3/0; |
| | First line | | | Arm 1: Pemetrexed 500 mg/m² q3w + bevacizumab 15 mg/kg q3w | 39.3% (95% CI, 26.5-53.3) | Arm 2: mPFS 7.6 months (95% CI, 3.0-10.7) | Arm 2: % Grade 3/ % Grade 4 Arm 2 (N=56): Neutropenia 9.3/0; Anemia 1.9/0; Leukopenia 1.9/0; Thrombocytopenia 0/3.7; Fatigue 18.5/0; Dyspnea 16.6/0; Asthenia 7.4/0; Thromboembolic events 5.6/1.9; Constipation 5.5/0; Dehydration 5.5/0; Diarrhea 5.5/0; Pneumonia 5.5/0; |
| | Primary endpoint=PFS | | | Arm 3: Pemetrexed 500 mg/m² q3w + carboplatin AUC=5 q3w (maximum of 4 cycles) | | Arm 3: mPFS 4.1 months (95% CI, 3.0-6.4) | Arm 3: % Grade 3/ % Grade 4 Arm 3 (N=52): Thrombocytopenia 13.5/5.8; Neutropenia 13.5/3.8; Anemia 7.7/1.9; Leukopenia 5.8/1.9; Fatigue 23.1/0; Dyspnea 9.6/0; |

<sup>a</sup>OS HR=0.65 (95% CI, 0.47-0.89; P=0.007)
| Authors, year (ref.), Treatment type, Endpoint<sup>a</sup> | Status | Study design/phase | Study population | Treatment<sup>b</sup> | ORR | mPFS and mOS | Grades 3/4 AEs occurring in patients in any arm and deaths<sup>c</sup> |
|----------------------------------------------------------|--------|-------------------|------------------|-------------------|-----|-------------|--------------------------------------------------|
| Schuette et al, 2013 (43) Ongoing | N=271 enrolled; n=251 evaluable; stage IIIB/IV non-squamous NSCLC; ECOG PS0-2; elderly (≥65 years) | Open-label, randomized/phase 3 trial (1:1) | | Arm 1: Pemetrexed (500 mg/m<sup>2</sup>) + bevacizumab (7.5 mg/kg) q3w followed by maintenance therapy with bevacizumab (7.5 mg/kg) | 31.4% | Arm 1: 64.4 months Arm 2: 65.4 months | Thromboembolic events 7.7/3.8 Asthenia 7.7/0 Pneumonia 5.8/0 3 treatment-related deaths (cerebrovascular accident, acute respiratory distress syndrome, pulmonary embolism) (Arm 2); 1 death (seizure) (Arm 3) |
| First line | Arm 1 (n=118): 112 PS0-1 6 PS2 46 maintenance | Arm 1 (n=133): 126 PS0-1 7 PS2 69 maintenance | | | | |
| Primary endpoint=PFS | | | | | | |

<sup>a</sup>Studies include those published in journals and those published in poster or abstract form. <sup>b</sup>Patients received folic acid and vitamin B12 and dexamethasone (19,40-42), except patients in the study by Schuette et al (43). <sup>c</sup>Includes all grade 3 or 4 hematologic AEs, deaths, and grade 3 or 4 nonhematologic AEs occurring in ≥5% of patients in any arm. AE, adverse event; All, overall population; AUC, area under curve; Carb, carboplatin; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; Gem, gemcitabine; HR, hazard ratio; HRQoL, health-related quality of life; m, median; n, number of patients in the specified category; N, population size; NR, not reported; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; Pem, pemetrexed; PFS, progression-free survival; PS, performance status; q2w, every 2 weeks; q3w, every 3 weeks; SCC, squamous cell carcinoma; vs, versus; WHO, World Health Organization; yrs, years.
patients were randomized 1:1 to pemetrexed (500 mg/m²) plus bevacizumab (Arm 1), pemetrexed and carboplatin combination followed by maintenance therapy with bevacizumab or pemetrexed-bevacizumab-carboplatin (Arm 2), or pemetrexed plus bevacizumab (Arm 3) for a maximum of 4 cycles. Arm 1, 25.4% (95% CI, 15.0-38.4) in Arm 2 and 39.3% (95% CI, 26.5-53.3) in Arm 3 (42). The median time to progression was 3.5 (95% CI, 1.6-6.4) months in Arm 1, 4.9 (95% CI, 3.1-8.0) months in Arm 2, and 5.3 (95% CI, 3.2-7.1) months in Arm 3. The median PFS was 2.6 (95% CI, 1.5-5.1) months in Arm 1, 3.5 (95% CI, 2.4-5.1) months in Arm 2 and 4.1 (95% CI, 3.0-6.4) months in Arm 3 (Table IV). The median OS was 7.6 (95% CI, 3.0-10.7) months in Arm 1, 8.7 (95% CI, 5.0-11.3) months in Arm 2, and 8.8 (95% CI, 5.4-13.4) months in Arm 3.

Grade 3 bevacizumab-associated AEs in Arm 2 were thromboembolic events (5.6%), hypertension (3.7%), and hemorrhage (1.9%), and in Arm 3 were thromboembolic events (7.7%), hypertension (1.9%) and proteinuria (1.9%) (42). Thromboembolic events were the only grade 4 bevacizumab-associated AEs (1.9% Arm 2 and 3.8% Arm 3). There were no treatment-related deaths in Arm 1. There were 3 treatment-related deaths (cerebrovascular accident, acute respiratory distress syndrome, and pulmonary embolism) in Arm 2 and 1 death (seizure) in Arm 3. Currently, this study is ongoing but not recruiting patients.

An open-label, single-arm study is ongoing, actively recruiting patients with non-squamous NSCLC who are at least 65 years old or have a PS of 2, and testing first-line pemetrexed and carboplatin combination followed by pemetrexed maintenance (Table III) (38).

4. Discussion

Because poor PS is an independent prognostic factor in NSCLC (12-16), PS scores are widely used by oncologists to guide treatment decisions. Historically, PS2 patients with advanced NSCLC had poor outcomes in randomized clinical trials (48-50), and early evidence suggested that therapy may have been detrimental in these patients (49,50). Thus, there has been a tendency to limit enrollment to patients with a PS ≤1. However, several recent trials have included PS2 NSCLC patients. The determination of PS scores as assessed by oncologists and other health care professionals can differ from patient-assessed PS (11). Nonetheless, health care profes-
ional-rated PS scores are prognostic, reliable and similar in accuracy to patient-reported PS scores, comparing favorably with the patient-reported PS scores (11,51,52).

Especially challenging are patients with a score between PS1 and PS2. The subjective determination of PS2 scores could affect the types of treatments offered (53). Also problematic are comorbid conditions (frequently measured by the Charlson Comorbidity Index) (54) that are independent of cancer; comorbidity may influence both PS and tolerance for cancer treatment. Despite the problems intrinsic to PS measurements, these measures are widely used and accepted given their reproducible capacity to assess prognosis and predict tolerability of treatment. However, with recent improvements in supportive care and improved tolerability and efficacy of anticancer agents in the treatment of advanced NSCLC, there has been a need to clarify the potential benefits of anticancer therapy in patients who have a PS of 2.

Until recently, treatment recommendations for PS2 patients were in part driven by the results of the cooperative group trial (EST 1581) published in 1986 (48). Between 1981 and 1983, EST 1581 randomized 486 patients with metastatic NSCLC to one of the four active regimens at the time: cyclophosphamide, doxorubicin, methotrexate and procarbazine; mitomycin, vinblastine and cisplatin; etoposide and cisplatin; or vindesine and cisplatin. Most of the severe toxicity occurred in the 19% of patients who had a PS of 2 at baseline (48). On the basis of these results, the authors suggested that patients with a PS of 2 be excluded from future phase 3 trials (48).

A later phase 3 cooperative group trial (ECOG 1594) investigating newer platinum-containing regimens initially included patients with advanced NSCLC and a PS of 2, but the protocol was later amended to exclude patients with a PS of 2 because of a high rate of serious AEs in these patients (49). On the basis of the toxicity and poorer outcomes of patients with a PS of 2 relative to those with a PS of 0-1, the authors concluded that the routine use of platinum-based combination chemotherapy in patients with poor PS was not recommended (49). A subsequent retrospective analysis of ECOG 1594 suggested that the worse outcomes of PS2 patients were related to the disease, not the treatment (50).

The ECOG 1599 trial was the first US cooperative group trial that specifically enrolled patients with a PS of 2 and NSCLC (55). In an attempt to maximize tolerability, this phase 2 trial randomized PS2 patients to receive first-line treatment with dose-attenuated carboplatin plus paclitaxel (the least toxic combination from ECOG 1594) and dose-attenuated gemcitabine plus cisplatin, which yielded a median OS of 7.9 months in patients with a PS of 2 in ECOG 1599 (50,55). One hundred patients were eligible to receive treatment. The 1-year OS rate was 25% for carboplatin plus paclitaxel and 19% for gemcitabine plus cisplatin. The authors concluded that platinum-based chemotherapy was feasible with acceptable toxicity in PS2 patients with NSCLC and that a randomized trial comparing a non-platinum single agent with a platinum doublet was needed in patients with a PS of 2 (55).

On the basis of historical studies and clinical experience, many clinical trials still exclude PS2 patients, leading to a paucity of data in this patient population (as evidenced by the few clinical trials reported in this review). Because of the lack of robust clinical trial data, there is still no consensus on the best chemotherapy for patients with poor PS. On the basis of emerging data, treatment guidelines are evolving. In ESMO guidelines published in 2010, single-agent chemotherapy was the preferred option in PS2 (and elderly) patients, although ‘selected’ PS2 patients (and elderly patients with good PS) could be offered combination chemotherapy (56). The most recent ASCO guidelines, published in 2011 (prior to the publication of some of the studies evaluating platinum doublets versus single-agent treatments in poor PS chemonaive patients), suggest that data are insufficient to make a recommendation for chemotherapy doublets in PS2 patients (Table 1) (3). The ESMO guidelines, published in 2014, now suggest carboplatin-based doublet therapy should be considered in eligible PS2 patients (Table 1) (4).

Although patients with a PS of 2 have worse outcomes when compared with those with a PS of 0-1, regardless of whether they receive pemetrexed (28,36,37,40,41) or other agents (48-50,57,58), recent data from completed trials show that among PS2 patients, chemonaive patients receiving combination treatment have improved outcomes with acceptable safety compared to those receiving single-agent treatment (19-24). Many of these studies include non-pemetrexed regimens. In the CALGB 9730 trial, in a preplanned subset analysis, chemonaive PS2 patients receiving carboplatin with paclitaxel experienced improved OS relative to PS2 patients receiving paclitaxel as a single agent (median OS 4.7 vs. 2.4 months; P=0.016) (21). In a phase 3 trial, Reynolds et al randomized chemonaive PS2 patients to gemcitabine as a single agent or gemcitabine plus carboplatin; patients receiving combination therapy experienced significantly improved ORR (21.1 vs. 6.3%; P=0.01). However, median OS and PFS were not statistically significant in the gemcitabine plus carboplatin group versus the single-agent gemcitabine group (median OS of 6.7 vs. 5.1 months; P=0.24) (median PFS of 3.8 vs. 2.7 months; P=0.14) (22). Gemcitabine and carboplatin is not an approved combination therapy.

Likewise, data from the European Union have also shown that chemonaive PS2 patients experience improved outcomes when treated with combination therapy (23). In the phase 3 CAPPA-2 study, chemonaive PS2 patients were randomized to receive first-line treatments of gemcitabine plus cisplatin and gemcitabine (23). The study was stopped after enrollment of 57 patients as a result of slow accrual. Among these patients, those receiving combination therapy experienced improved median OS (5.9 vs. 3.0 months; P=0.039), median PFS (3.3 vs. 1.7 months; P=0.017) and response (18 vs. 4%; P=0.19) without a substantial increase in toxicity.

Pemetrexed is better tolerated than gemcitabine, paclitaxel and docetaxel and has been shown to be at least equally effective in non-squamous NSCLC patients with PS 0-1 (28,31,44,59). Thus, given the previously mentioned results supporting the use of platinum doublets in PS2 chemonaive NSCLC patients, it is tenable that a platinum doublet containing pemetrexed would also be promising as first-line therapy in PS2 patients with advanced NSCLC. This was demonstrated in the study by Zukin et al, in which PS2 patients receiving first-line pemetrexed plus carboplatin had improved OS (with acceptable safety) relative to patients receiving single-agent
pemetrexed (19). Pemetrexed and carboplatin is not an approved combination therapy.

Completed results are pending in the ongoing study, ToPPs, in which chemonaive patients were randomized to receive pemetrexed plus bevacizumab and pemetrexed plus bevacizumab and carboplatin. Preliminary results show numerically improved outcomes compared to patients receiving pemetrexed monotherapy (42). Bevacizumab and pemetrexed is not an approved combination therapy.

To our knowledge, there are no published data assessing pemetrexed as second-line cytotoxic chemotherapy in PS2 patients aside from the study by Hanna et al (28), and there are few clinical data on NSCLC patients with PS2 who received maintenance cytotoxic chemotherapy. To date, there are no pemetrexed trials on maintenance therapy in PS2 patients. There have been a few studies on the role of maintenance therapy with gemcitabine in PS2 patients. In the Central ECOG trial of continuation maintenance with gemcitabine after cisplatin-gemcitabine induction therapy, Brodowicz et al reported that a survival benefit for maintenance therapy was observed only in patients with good PS (60). For patients with a KPS >80 (n=99), median OS was 8.3 months with BSC and 22.9 months with gemcitabine (HR=2.1; 95% CI, 1.2-3.8). For patients with a KPS ≤80 (n=107), median OS was 7.7 with BSC and 7.0 months with gemcitabine (HR=0.8; 95% CI, 0.5-1.3). However, the authors caution that this was an unplanned subset analysis. Belani et al assessed gemcitabine continuation maintenance vs. BSC after carboplatin-gemcitabine induction chemotherapy (61). In this trial, 25% of patients had a PS ≥2 at the time of randomization. Although this trial did not specifically report results for PS2 patients, survival was not improved with gemcitabine maintenance therapy for the overall population. However, maintenance gemcitabine was tolerable, albeit with higher rates of grade 3-4 toxicities. With more effective induction regimens that have better therapeutic indices, it might be possible in the future to explore the role of maintenance treatment in patients with advanced NSCLC and a PS of 2.

Recently, in a meta-analysis including 2,671 patients with non-squamous NSCLC and good PS who were treated with a pemetrexed-containing regimen as first- or second-line or maintenance therapy, the effect of pemetrexed on OS was similar in younger and older patients as evidenced by the pooled HR ratio close to 1. The authors concluded that pemetrexed is an efficacious treatment for advanced non-squamous NSCLC, regardless of patient age (62). The final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the phase 3 PARAMOUNT study showed that continuation maintenance pemetrexed had comparable survival and toxicity profiles in the elderly and non-elderly subgroups (63). In the present review, we identified a German multicenter study in elderly patients, in which the combination of pemetrexed-bevacizumab-carboplatin demonstrated efficacy, particularly in PS0-1 patients, with an acceptable toxicity profile (43).

It should be noted that this review has several limitations. These include a small number of clinical trials, some of which were subject to retrospective subset analyses. Although prospective clinical trials were included in this review, patient numbers are relatively small and patient enrollment may have been subject to investigator bias with respect to the assessment of PS2. It is also possible that the PS2 patient populations enrolled in these clinical trials may not be representative of patients in community practice in that patients with excessive or specific comorbidities may not have met the inclusion criteria for a clinical trial. Additionally, although pemetrexed (with vitamin supplementation) is now indicated for use in patients with non-squamous NSCLC (26,32), some of the earlier clinical trials included in this review enrolled patients with squamous NSCLC and/or did not require vitamin supplementation, preventing meaningful subset analyses. Other limitations of this review are as follows: i) investigator bias in assessing progressive disease; ii) lack of placebo-controlled trials; and iii) only 1 trial that met its primary endpoint.

5. Conclusion

Patients with a PS of 2 represent a heterogeneous population. Doublet regimens can improve the response rate and survival in PS2 patients (19-24). Consequently, doublet combinations, such as pemetrexed plus carboplatin, are an option in PS2 patients with non-squamous NSCLC (19). Pemetrexed plus carboplatin is not an approved combination therapy. Single-agent therapy remains an option for PS2 chemonaive patients with excessive comorbidities and those who cannot tolerate combination therapy. Finally, supportive care with a focus on palliation of symptoms is important for all patients; quality of life should be a key determinant in selecting treatment.

Acknowledgements

The authors thank Dr Andrew Koustenis, of Eli Lilly and Company, for providing a critical review of the manuscript. Writing and editorial assistance for the development of this manuscript was provided by inVentiv Health Clinical with the financial support of Eli Lilly and Company. The authors would like to acknowledge Sharad Wankhade, PhD, and Noelle Gasco, employees of inVentiv Health Clinical, for writing and editorial support. C.V.G. and C.O. are employees of Eli Lilly and Company. R.Z. received financial support for travel and research from Eli Lilly and Company. D.R.S. has no conflict of interest. Eli Lilly and Company provided financial support for the preparation of the article.

References

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 (Internet). International Agency for Research on Cancer, Lyon, France, 2013. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed March 5, 2014.
2. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311: 899-909, 1995.
3. Azzoli CG, Temin S, Aliff T, Baker S, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, et al: 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29: 3825-3831, 2011.
4. Reck M, Popat S, Reinmuth N, De Ruyscher D, Kerr KM and Peters S: ESMO Guidelines Working Group: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 (suppl 3): iii27-iii39, 2014.
5. NCCN: NCCN Clinical Practice Guidelines in Oncology. Non-small cell lung cancer, V.5. 2015. National Comprehensive Cancer Network, 2015. http://www.nccn.org/professionals/physician_ gls/pdf/nscl.pdf. Accessed March 19, 2015.

6. Oken MM, Creech RH, Torney DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.

7. Schag CC, Heinrich RL and Ganz PA: Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol 2: 187-194, 1984.

8. Buccheri G, Ferrigno D and Tamburini M: Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 32A: 1135-1141, 1996.

9. Kelly K: Challenges in defining and identifying patients with non-small-cell lung cancer and poor performance status. Semin Oncol 31 (suppl 11): 3-7, 2004.

10. Radzickowska E, Glaz P and Roszkowski K: Lung cancer in women: Age, smoking, histology, performance status, stage, initial treatment and survival. Population based study of 20 561 cases. Ann Oncol 13: 1087-1093, 2002.

11. Lilenbaum RC, Cashy J, Hensing TA, Young S and Cella D: Prognostic factors in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9: 1618-1626, 1991.

12. Ando M, Ando Y, Sugiura S, Minami H, Saka H, Sakai S, Shimokata K and Hasegawa Y: Prognostic factors for short-term survival in patients with stage IV non-small-cell lung cancer. Jpn J Cancer Res 90: 249-253, 1999.

13. Brandi LE, Davies D and Mackillop WJ: Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 122: 1037-1057, 2002.

14. Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65: 25-32, 1980.

15. Takigawa N, Segawa Y, Okahara M, Maeda Y, Takata I, Lilenbaum R, Ackland SP: Phase II trial of pemetrexed disodium (ALIMTA, ZINNER) in chemotherapy-naive patients with advanced non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374: 1432-1440, 2009.

16. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TCY, Pless M, Muller T, et al: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004.

17. Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et al: Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care in patients with non-small-cell lung cancer (PARAMOUNT): A randomised, double-blind, phase 3, randomised controlled trial. Lancet Oncol 13: 247-255, 2012.

18. Penges LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, et al: PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 31: 2985-2992, 2013.

19. Skagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukan M, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.

20. European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP): Alimta. EMEA/H/C/000564. 2011. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000564/human_med_000638.jsp&mid=WC0b01ac058001d124. Accessed March 19, 2015.

21. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Rufifie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with advanced non-squamous non-small-cell lung cancer (SPIRITS): A randomised, open-label, phase 3 study. Lancet Oncol 9: 500-508, 2008.

22. Zikan M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, do Nascimento YN, Murad A, Franke FA, Precivale M, Aragona LR, et al: Phase-II trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group Performance Status of 2. J Clin Oncol 31: 2849-2853, 2013.

23. Lee L, Cheung WY, Atkinson E and Krzyzanowski MK: Impact of comorbidity on chemotherapy use and outcomes in solid tumours: A systematic review. J Clin Oncol 29: 106-117, 2011.

24. Zukan M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, do Nascimento YN, Murad A, Franke FA, Precivale M, Aragona LR, et al: Phase-II trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group Performance Status of 2. J Clin Oncol 31: 2849-2853, 2013.

25. Bidoli P, Molinier O, Sahoo TP, Laack E, Wu Y-L, Bover I, Begbie S, Tzekova V, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 374: 1432-1440, 2009.

26. Shih C, Habeck LL, Mendelsohn LG, Chen VJ and Schultz RM: Multiple folate enzyme inhibition: Mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 38: 135-192, 1998.

27. Altima [package insert]. Indianapolis, IN: Eli Lilly and Company; 2013.

28. Lilenbaum R, Creech RH, Torney DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982.

29. Lilenbaum R, Villaflor VM, Langer C, O’Byrne K, O’Brien M, Ross HH, Socinski M, Oldham FB, Sandilac L, Singer JW, et al: Single-agent versus combination chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2: Prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol 4: 869-874, 2009.

30. Zukan M, Barrios CH, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Tsao TCY, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, et al: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in patients with advanced non-small-cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
40. Blakely LJ, Schwartzberg L, Keaton M, Schnell F, Henry D, Epperson A and Walker MS: A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIIB/IV non-small cell lung cancer. Lung Cancer 66: 97-102, 2009.

41. Grenberg BH, Bremnes RM, Flottem E, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, von Plessen C, Stornes F, Tollati T, et al: Phase III study by the Norwegian lung cancer study group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non small cell lung cancer. J Clin Oncol 27: 3217-3224, 2009.

42. Lilienbaum R, Hainsworth J, Joseph M, Shipley D, Hagan K, Thompson D, Greco F, Burris H and Spigel D: Randomized phase II study of pemetrexed v. pemetrexed/bevacizumab v. carboplatin/pemetrexed/bevacizumab in patients with previously untreated advanced non-squamous non-small-cell lung cancer and poor performance status. J Thorac Oncol 8 (Suppl 2): S889-S890, 2013.

43. Schuette W, Nagel S, Schneider CP, Engel-Riedel W, Schumann C, Kohlhase I, Serke M, Hoefken G, Kortsik C, Reck M, et al: 65 plus: A randomized phase III trial of pemetrexed and bevacizumab versus pemetrexed, bevacizumab, and carboplatin as first-line treatment for elderly patients with advanced nonsquamous, non-small cell lung cancer (NSCLC). ASCO Annual Meeting. J Clin Oncol 31: abs 8013, 2013.

44. Shepherd FA, Dancey J, Ramilaur R, Mattson K, Gralla R, O'Rourke M, Lebain T, Gressot L, Vincent M, Burkes R, et al: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000.

45. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kelman L, Miller V, Lee JS, Moore M, et al: Randomized phase III trial of docetaxel versus vinorelbin or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18: 2354-2362, 2000.

46. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, Simms L and Shepherd FA: The differential efficacy of pemetrexed according to NSCLC histology: A review of two Phase III studies. Oncologist 14: 253-263, 2009.

47. Scagliotti G, Brodowicz T, Shepherd FA, Zielinski C, Vansteenkiste J, Manegold C, Simms L, Fossella F, Sugarman K and Belani CP: Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 6: 64-70, 2011.

48. Ruckdeschel JC, Finkelstein DM, Eittinger DS, Creech RH, Mason BA, Joss RA and Vogl S: A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4: 14-22, 1986.

49. Schiller JH, Harrington D, Belani CP, Langer C, Johnson DH: Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.

50. Sweeney CJ, Zhu J, Schiller AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D and Johnson DH: Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A Phase II trial in patients with metastatic non-small cell lung carcinoma. Cancer 92: 2639-2647, 2001.

51. Ando M, Ando Y, Hasegawa Y, Shimokata K, Minami H, Wakai K, Ohno Y and Saka K: Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer. Br J Cancer 85: 1634-1639, 2001.

52. Blagden SP, Charman SC, Sharples LD, Magee LR and Gilligan D: Performance status score: Do patients and their oncologists agree? Br J Cancer 89: 1022-1027, 2003.

53. Moreira JR, Breschet JM, Westeel V, Gounant V, Lebeau B, Vaylet F, Barlesi F, Urban T, Souquet P-J, Debieuvre D, et al: Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study). Lung Cancer 70: 301-307, 2010.

54. Charlson ME, Pompei P, Ales KL and MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 40: 373-383, 1987.

55. Langer C, Li S, Schiller J, Tester W, Rapoport BL and Johnson DH: Eastern Cooperative Oncology Group: Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 25: 418-423, 2007.

56. D'Addario G, Früh M, Reck M, Baumann P, Klepetko W and Felip E: ESMO Guidelines Working Group: Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21 (suppl 5): v16-v119, 2010.

57. Perrone F, Di Maio M, Gallo C and Gridelli C: Outcome of patients with a performance status of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). J Clin Oncol 22: 5018-5020, 2004.

58. Soria JC, Brigand D and Le Chevalier T: Do all patients with advanced non small cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol 12: 1667-1670, 2001.

59. Patel JD, Socinski MA,aron EB, Reynolds CH, Spigel DR, Olsen MR, Herrman RC, Jotte RM, Beck T, Richards DA, et al: PointBreak: A randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab followed by maintenance bevacizumab in patients with stage IIIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol 31: 4349-4357, 2013.

60. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramilaur R, Ghizeran N, Ciuleanu T, Cucicve B, Gyurkovits K, Ulperger E, et al: for the Central European Cooperative Oncology Group: Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: A phase III trial. Lung Cancer 52: 155-163, 2006.

61. Belani CP, Waterhouse DM, Ghazal H, Ramalingam SS, Bordoni R, Greenberg R, Levine RM, Waples JM, Jiang Y and Reznikoff G: Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting. J Clin Oncol 28: abs 7506, 2010.

62. Paz-Ares L, Zimmermann A, Ciuleanu T-E, Bunn PA, San Antonio B, Denne J, Iturria N, John WJ and Scagliotti GV: Meta-analysis examining impact of age on pemetrexed (pem) efficacy for the treatment of advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol 32: abs e19040, 2014.

63. Gridelli C, de Marinis F, Thomas M, Prabhak S, El Kouri C, Blackhall F, Bustin F, Pujol JL, John WJ, San Antonio B, et al: Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase II trial. J Thorac Oncol 9: 991-997, 2014.